Immunovaccine is a clinical-stage vaccine development company focused on the advancement of its patented DepoVax vaccine adjuvanting platform and product candidates for cancer therapy, infectious disease and animal health. Demonstrating safety and immunogenicity potential, Immunovaccine has advanced its platform technology and proprietary cancer vaccines into Phase I human clinical trials. The company is also advancing a broad infectious disease pipeline that includes vaccines for malaria, RSV and anthrax, and a collaborative anti-cocaine vaccine program. For more information, visit the company’s Web site at www.imvaccine.com.

The 6th Annual OneMedForum is a gathering of leading investors and management of some of the most promising emerging life science companies in Asia and North America. Through panels, workshops and up-close programming with top industry leaders, attendees explore strategies for company growth finance with healthcare investors looking for outsized returns. For more information, please visit www.onemedforum.com.

Let us hear your thoughts below: